<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514942</url>
  </required_header>
  <id_info>
    <org_study_id>MIvsDCI_PCOS/IR</org_study_id>
    <nct_id>NCT01514942</nct_id>
  </id_info>
  <brief_title>Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <brief_summary>
    <textblock>
      Insulin resistance has important implications in the pathogenesis of the polycystic ovary
      syndrome (PCOS) and insulin-sensitizing drugs are considered a useful therapeutic approach.

      Reduction of insulin levels with administration of insulin sensitizing agents has been found
      to be beneficial in lowering both hyperinsulinemia, hyperandrogenemia, and restoring
      ovulation. Metformin alone or in combination with oral contraceptives (OCs) has been widely
      used in the long term treatment of women with PCOS in whom it modifies the ovarian
      morphology, improves intraovarian androgen levels, and enhances systemic and local insulin
      resistance. Despite to these beneficial effects, several side effects have been reported due
      to the long term administration of this drug.

      In the recent years, inositol has found more and more space in the reproductive clinical
      practice. Indeed, inositol have been classified as &quot;insulin sensitizing agent&quot; and it is
      mainly used as a chronic treatment for PCOS. Inositol exists in 9 different isomers and in
      particular several studies on Myo-inositol and D-chiro-inositol were reported.

      In this study myo-inositol versus D-chiro-inositol treatments were compared to placebo in
      women with PCOS and with or without insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Body Mass Index (BMI)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Menstrual cycle</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Score acne (acne grading system by Cremoncini et al)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Score hirsutism (Ferriman-Gallwey score)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Alopecia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Glucose Tolerance Test (OGTT)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucagon levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>C-peptide test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Myo-inositol serum concentration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>D-chiro-inositol serum concentration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), and Estradiol (E2) levels test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prolactin (PRL) levels test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Thyroid-stimulating hormone (TSH), free thyroid hormone (fT3 and fT4), and alpha-1 antitrypsin (AAT) test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Total and free testosterone levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex hormone binding globulin (SHBG) test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>17-Hydroxyprogesterone (17-OHP) levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>delta 4-androstenedione levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>progesterone levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adrenocorticotropic Hormone (ACTH) stimulation test</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ovarian size and morphology</measure>
    <description>Ovarian ultrasound scan for the assessment of size and morphology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antral follicle counts</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Stromal/Cortical ratio in the ovary</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <description>Transvaginal ultrasound measurement of endometrial thickness performed between day 3 and 5 of the menstrual cycle.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Insulin resistant patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-insulin resistant patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + Folic acid</intervention_name>
    <description>Myo-inositol (2g) Folic acid (200mcg) (2 per day)</description>
    <arm_group_label>Insulin resistant patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + Folic acid</intervention_name>
    <description>Myo-inositol (2g) Folic acid (200mcg) (2 per day)</description>
    <arm_group_label>Non-insulin resistant patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-chiro-inositol, manganese, folic acid, vit B12</intervention_name>
    <description>D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)</description>
    <arm_group_label>Insulin resistant patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-chiro-inositol, manganese, folic acid, vit B12</intervention_name>
    <description>D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)</description>
    <arm_group_label>Non-insulin resistant patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic acid, vit B12</intervention_name>
    <description>Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)</description>
    <arm_group_label>Insulin resistant patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic acid, vit B12</intervention_name>
    <description>Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)</description>
    <arm_group_label>Non-insulin resistant patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women fulfilled two out of three diagnostic criteria for PCOS

        Exclusion Criteria:

          -  Women with pre-existing secondary endocrine disorders

          -  Women with personal history of hypertension, diabetes mellitus or cardiovascular
             disorders

          -  Women who received treatment with other drugs for the previous 6 months before
             entering the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituto di Patologia Ostetrica e Ginecologica</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.</citation>
    <PMID>19499845</PMID>
  </reference>
  <reference>
    <citation>Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010 Apr;26(4):275-80. doi: 10.3109/09513590903366996.</citation>
    <PMID>20222840</PMID>
  </reference>
  <reference>
    <citation>Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47-60.</citation>
    <PMID>11900279</PMID>
  </reference>
  <reference>
    <citation>Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010 Nov-Dec;16(11-12):543-52. doi: 10.2119/molmed.2010.00107. Epub 2010 Aug 27. Review.</citation>
    <PMID>20811656</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Myo-inositol</keyword>
  <keyword>D-chiro-inositol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Manganese</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

